Resources
BeiGene Medical Europe

Results of a phase 3 randomized trial of Zanubrutinib vs. Ibrutinib

 Back View
Results of a phase 3 randomized trial of Zanubrutinib vs. Ibrutinib
 ABSTRACT   06/2020
 View

For more information about this resource, please submit a medical information request.

Aspen: Results of a phase 3 randomized trial of Zanubrutinib vs. Ibrutinib for patients with Waldenström macroglobulinemia

Rating

Rate this resource

Related resources

Zanubrutinib - Mode of Action
Zanubrutinib - Mode of Action
Ongoing clinical trials: Hematologic cancers
Ongoing clinical trials: Hematologic cancers
Exploring the changing landscape in Waldenström’s macroglobulinaemia: How will emerging BTK inhibitors alter patient outcomes?
Exploring the changing landscape in Waldenström’s macroglobulinaemia: How will emerging BTK inhibitors alter patient outcomes?
 Back

Nice to see you!

For newest details on our ESMO materials in a personal video meeting, please click here!
Service